bluuebunny/crossref_metadata_2025_split huggingface dataset:
OR63. The benefit of virtual anti-hypertensive diets campaign towards the changes of knowledge, attitude, practice, and reduction of blood pressure in the society during covid-19 pandemic
Authors: Andrianto Meity Ardiana , Yutha Alqi , Khrisna Bagus Putra Dharma , Nugraha Ricardo Adrian , Putra Tony Santoso , Shahab Achmad Rizal , Andrianto Henny , Kikuko Irawati Hajar , Puspitasari A’rofah Nurlina , Hajjrin Maltadilla Ratu 
Published: April 2022

Abstract

Background
Department of Cardiology and Vascular Medicine created a virtual education series about dietary guideline that refers to DASH by adapting the local wisdom of the Surabaya community.

Aims
We aimed to evaluate the impact of Airlangga Comprehensive Anti-Hypertensive Diets Virtual Education Series towards knowledge, attitude, practice, and reduction of blood pressure in the primary care setting during COVID-19 pandemic.

Methods
This type of online action research is quantitative with a quasi-experimental design that designs using one group pretest-posttest, when this study was conducted in October-December 2020. The population in this study were all patients with hypertension who were treated in Mojo primary health care setting. A purposive sampling technique were done to receive 110 participants using online questionnaire.

Results
A total of 110 participants were included in the analysis, 55 in the intervention group and 55 in the control group. Following the Airlangga Comprehensive Anti-Hypertensive Diets Virtual Education Series implementation, the only parameter that showed significant improvement were knowledge and attitude (p&lt;0 .001). There is no significant change in the skill parameters (p=0.131) and blood pressure parameters (p=0.433) .

Conclusion
Airlangga Comprehensive Anti-Hypertensive Diets Virtual Education Series implementation in our study population seems to be effective to improve knowledge and attitude of participants, however, this program seems to be ineffective to improve skill and blood pressure reduction in participants. Future study with longer durations and more comprehensive programme needs to be done to scrutinize the clinical impact of this program nationwide.
OR64. The differences of sum ST-deviation resolution of STEMI patients who underwent pharmaco-invasive strategy compared to primary percutaneous coronary intervention strategy in DR. Sardjito Hospital
Authors: Amin M I , Taufiq N , Maharani E 
Published: April 2022

Abstract

Aims
This study aims to determine the difference between sum ST-segment deviation (∑-STD) resolution in ST-segment elevation myocardial infarction (STEMI) patients who underwent Pharmaco-invasive strategy as compared to the Primary PCI strategy.

Methods and Results
This study design was a retrospective cohort. It measured the ∑-STD resolution in two groups. Forty-five patients who underwent both Pharmaco-invasive and Primary PCI strategy were compared. The cut-off &gt; 50% was considered significant resolution and &lt;50% was considered insignificant resolution. The difference was analyzed using comparative analysis and logistic regression test. The ∑-STD resolution between STEMI patients who underwent Pharmaco-invasive strategy compared with Primary PCI strategy was 26.63% (84.40% in the Pharmaco-invasive vs. 57.77 %% in Primary PCI group, RR = 1.46 (95% CI, 1.10-1.93), p = 0,005).

Conclusion
The ∑-STD resolution was significantly higher in STEMI patients who underwent Pharmaco-invasive strategy as compared to Primary PCI strategy.
OR68. The impact of coronavirus disease 2019 pandemic on acute coronary syndrome hospitalizations, treatments, and outcomes: a dual-center observational study
Authors: Amshar M , Ardining H , Nathania M , Akbar F , Ulfiarakhma D , Napu R , Karimullah M D H , Widyantoro B 
Published: April 2022

Abstract

Background and Aims
Since March 2020, transmission of coronavirus disease 2019 (COVID-19) in Indonesia have led to substantial decline in non-COVID-19 hospitalizations and healthcare services. We ought to determine the impact of COVID-19 pandemic on acute coronary syndrome (ACS) hospitalizations, treatments, and outcomes.

Methods and Results
We conducted a dual-center observational study in Bogor City General Hospital and Kediri General Hospital, Indonesia. We included all ACS patients between January-June 2020. Subjects were divided into two groups: pandemic period (admitted in March-June 2020) and pre-pandemic period (admitted in January-February 2020). 279 subjects were involved (107 pandemic vs 172 pre-pandemic). Monthly average ACS admissions reduced by 68.6% during pandemic period compared to pre-pandemic period. Proportion of STEMI subjects was significantly higher during pandemic compared to pre-pandemic (56.1% vs 38.4%; p = 0.004). Proportion of Killip 3-4 subjects was also significantly higher during pandemic compared to pre-pandemic (26.2% vs 14.5%; p = 0.016). However, reperfusion therapy (PCI or fibrinolytic) proportion for STEMI subjects was significantly lower during pandemic compared to pre-pandemic (16.7% vs 31.8%; p = 0.049), although there was no significant difference in onset time of ACS symptoms before hospitalization (p = 0.793). In-hospital mortality rate was significantly higher during pandemic compared to pre-pandemic (15.9% vs 8.1%; p = 0.045).

Conclusion
There was a significant decline in ACS hospitalizations, increased proportion of STEMI and KILLIP 3-4 patients, and higher in-hospital mortality rate in the pandemic period compared to pre-pandemic period. Paradoxically, reperfusion therapy proportion in STEMI patients has reduced significantly during pandemic period.
OR70. The Impact of Mitral Valve Replacement on Right Ventricle Longitudinal Strain Case Study in Dr Kariadi General Hospital Semarang
Authors: Elfa S A , Rifqi Sodiqur , Arif Nugroho Hardian M 
Published: April 2022

Abstract

Background
Right ventricular (RV) function often overlooked in routine echocardiography examination even some research found its association with outcome in various cardiovascular and cardiac surgery setting. Deterioration of RV function occurred immediately after cardiac surgery. Compared with conventional echocardiography examination, free wall RV longitudinal strain (RVLS) is less load dependent and have a better association with cardiac magnetic resonance imaging, the gold standard for the examination of RV function

Objective
To investigate the changes in free wall RVLS pre- and post-surgical mitral valve replacement (MVR) and the factors that contribute to postoperative free wall RVLS change.

Methods
Patients undergoing MVR were enrolled consecutively. Free wall RVLS was assessed before the operation and 1-2 weeks after the operation.

Results
There were 29 samples in this study, consisted of 16 samples with mitral stenosis and 13 samples with mitral regurgitation. Paired T-test showed significant change between free wall RVLS pre- and post-operative (-18.8±3.41 and -13.5±3.21, respectively) with a difference of 5.07 (1.40-15.34), p&lt;0.001. Analysis on preoperative and operative factors, such as preoperative left ventricular ejection fraction (LVEF), probability of pulmonary hypertension (PH), cardiopulmonary bypass (CPB) time, aortic cross clamp (Aox) time, and basal, mid, and longitudinal RV diameters, showed no significant association with postoperative free wall RVLS change.

Conclusion
There is significant decrease of free wall RVLS early after MVR. The decrease in postoperative free wall RVLS isn’t associated with factors such as preoperative LVEF, probability of PH, RV diameters CPB time and Aox time
OR75. The role of tricuspid annular plane systolic excursion for STEMI patients in the national PCI center
Authors: Shabrina N N , Tobing D 
Published: April 2022

Abstract

Aims
Tricuspid annular plane systolic excursion (TAPSE) is one of the most established echocardiographic parameters to assess global function of the right ventricle (RV). This study sought to evaluate TAPSE to predict early outcomes and ascertain whether its value adds beneficial prognostic information to patients with myocardial infarction.

Methods and Results
Of all 899 patients who were diagnosed with ST-segment elevated myocardial infarction (STEMI) between July 2018 to June 2019, 576 patients underwent echocardiography examination within 24-hour of onset. The subjects were categorized into two groups: TAPSE ≤18 mm (n = 265) and TAPSE &gt;18 mm (n = 311). Primary outcomes were the incidence of cardiogenic shock, cardiac arrest, and in-hospital mortality.
A total of 576 patients (513 males, mean age 55±10) with STEMI diagnosis who underwent percutaneous coronary intervention were enrolled to this study. In the overall cohort, TAPSE ≤18 mm was statistically associated with greater incidence of cardiogenic shock (p = 0.001), cardiac arrest (p = 0.002), and in-hospital mortality (p = 0.001). Multivariate analysis showed that TAPSE ≤18 mm was an independent predictor of cardiogenic shock (OR, 2.951; 95% CI, 1.507 to 5.781), cardiac arrest (OR, 2.500; 95% CI, 1.381 to 4.527), and in-hospital mortality (OR, 2.868; 95% CI, 1.460 to 5.632).

Conclusion
The assessment of TAPSE that represents RV function among STEMI patients can be considered as a prognostic factor regarding early outcomes. Long-term follow-up is necessary to obtain more comprehensive prognostic information.
OR76. The Roles of Growth Differentiation Factor-15 for Prediction of Major Adverse Cardiac Event among Patients with Acute Myocardial Infarction
Authors: Tridamayanti A , Wasyanto T , Yasa T A 
Published: April 2022

Abstract

Background and Aims
Growth Differentiation Factor-15 (GDF-15) is a systemic inflammation marker that has emerged as a biomarker that capable to predicting cardiovascular events. Recent studies suggest that GDF-15 is elevated in patients with acute myocardial infarction, but the prognostic remains incompletely defined. This study aimed to investigate the difference between high and low GDF-15 levels with major cardiac adverse events (MACE) in patients with acute myocardial infarction.

Methods and Results
This cohort study was conducted with total of 64 acute myocardial infarction patients. GDF-15 was measured at admission and clinical data and 3 months follow up events was registered. MACE at hospitalization occurred in 43.75% of patients, whereas MACE at three months of observation occurred in 18.6% of patients. After adjustment multivariate analysis, higher levels of GDF-15 was independently associated with risk of MACE at 3 months follow up (OR 1.501; p = 0.003). The cut-off point value of GDF-15 was obtained 2256 pg/mL (AUC 0.848; 95% p = 0.001). Risk model with Kapplan Meier showed significant association between high GDF-15 levels (≥ 2256 pg/mL) and the incidence of MACE during hospitalization (HR 2.492; 95% CI 1.126-5.518; p = 0.0024) and MACE at 3 months follow up (HR 14.693; 95% CI 1.877-115.047; p &lt; 0.001)

Conclusion
GDF-15 was significantly associated with the risk of MACE at hospitalization and at 3 months of observation after acute myocardial infarction
M1. Association between Subclinical Hypothyroidism and Heart Failure: A Systematic Review and Meta-Analysis
Authors: Faizah N N , Effendi G B 
Published: April 2022

Abstract

Background and Aims
The correlation between subclinical hypothyroidism and heart failure has been increasingly investigated, but still controversial. We performed a systematic review and meta-analysis to evaluate the association between subclinical hypothyroidism and the incidence of heart failure.

Methods and Results
Two reviewers systematically searched literature evaluating the association between subclinical hypothyroidism and heart failure on PubMed from inception to June 2021. Subclinical hypothyroidism was defined as thyroid-stimulating hormone (TSH) of 4.5 to 19.9 mIU/L with normal T4 level in the absence of symptoms. The quality of the studies was reported using the Newcastle-Ottawa scale (NOS). A meta-analysis was conducted using RevMan 5.4 software by analyzing the hazard ratio (HR) with 95% confidence intervals (95%CIs) using a random and fixed-effects model.
A total of six cohort studies involving 602,176 subjects were included. Among the participants, 14,995 (2.5%) had subclinical hypothyroidism. Our pooled analysis showed that individuals with subclinical hypothyroid had an increased risk of heart failure compared to those with euthyroid (HR = 1.03; 95%CI = 0.95-1.11, p = 0.50); however, it was not statistically significant. Furthermore, subgroup analysis was done based on TSH level divided into 4.5-6.9 mIU/L, 7.0-9.9 mIU/L, and ≥10.0 mIU/L. Increased risk of heart failure was significantly associated with TSH level of ≥ 10.0 mIU/L (HR = 1.93; 95%CI = 1.24-3.01, p = 0.004).

Conclusion
Higher TSH level in subclinical hypothyroidism is associated with an increased risk of heart failure, particularly for TSH ≥10 mIU/L.
M4. Catheter ablation versus medical therapy for atrial fibrillation treatment in older adults: a systematic review and meta-analysis
Authors: Tandaju J R , Mangkuliguna G 
Published: April 2022

Abstract

Background
Prompt treatment of atrial fibrillation is essential to reduce mortality and morbidity and increase quality of life. Catheter ablation remains one of effective treatments, yet its efficacy on elderly was unknown. In addition, elderly have different drug tolerance, thus results on the general population were not reliable.

Aim
Compare the outcomes of catheter ablation (CA) versus antiarrhythmic drug (ARD) for older patients (55 and above) with AF.

Methods
The protocol has been registered in the International Prospective Register of Systematic Reviews (PROSPERO) (CRD42021262067).

Results
Nine studies involving 2,307 patients were included. The majority of studies had low risk-of-bias. CA was associated with lower mortality (OR = 0.40; 95% CI [0.27,0.61]; p &lt; 0.0001), recurrence rate (OR = 0.31; 95% CI [0.15,0.65]; p = 0.002) and higher quality of life measured with SF-36 (MD = 4.78; 95% CI [2.28,7.28]; p = 0.0002) compared to those who received ARD only. Improvement in left ventricular ejection fraction (MD = 4.53; 95% CI [2.18,6.87]; p = 0.0002) and brain natriuretic peptide level (MD=-108.85; 95% CI [-195.59,-22.11]; p = 0.01) were also observed. There were some risks of cerebrovascular accidents post-ablation (OR = 0.46; 95% CI [0.25,0.85]; p = 0.01).

Conclusion
CA seems to offer more clinical benefits than ARD among older patients, however its execution must be warranted by patient-tailored therapy choice.
M7. Effects of the angiotensin receptor–neprilysin inhibitor/sacubitril-valsartan administration on quality of life and outcome in heart failure with reduced ejection fraction: a meta analysis
Authors: Dewi Kadek Intan Murti , Pintaningrum Yusra 
Published: April 2022

Abstract

Background and Aims
Improved quality of life is a mayor treatment goal in heart failure. Based on the PARADIGM-HF trial, ARNI was found improved quality of life in heart failure with reduced ejection fraction (HFrEF). The aims of this study are to evaluate the quality of life and outcome patient HFrEF after ARNI administration.

Methods and Result
Published scientific articles is searched through PubMed database with inclusion criteria were Randomized Control Trial (RCT) or observational study in the last 10 years (2014 - 2021), the QoL is measured by Kansas City Cardiomyopathy Score (KCCQ). A total of 4 RCTs and 3 observational studies were selected. There was significantly increase in KCCQ Overall Summary score (MD = 2.01 [95% CI, 1.07, 2.96], p &lt; 0.00001). There was also significantly increase in KCCQ physical limitation domain (MD = 1.21[95% CI, 0.12, 2.30], p = 0.03), QoL domain (MD = 2.66[95% CI, 0.64, 4.69], p = 0.010) and social limitation domain (MD = 1.97[95% CI, 0.98, 2.95], p &lt; 0.0001). The relative risk in HFrEF patients for first hospital admission was 0.82 (95% CI, 0.77, 0.87, p &lt; 0.00001) and relative risk for cardiovascular death was 0.81(95% CI, 0.76, 0.87, p &lt; 0.00001). Hypotension was found as significant adverse event after treatment with ARNI (RR = 1.57 [95% CI, 1.41, 1.75], p &lt; 0.00001).

Conclusion
ARNI was found significantly improved quality of life, reduced morbidity and mortality in patient HFrEF compared with control but might causes a serious adverse event such as hypotension. Due to limitation data of adverse event, a further investigation might be needed.
M8. Electrocardiogram findings as predictor of atrial fibrillation recurrence after intervention: systematic review and meta-analysis
Authors: Tandaju J R , Wardhana I L , Inayati F , Moegandi R P , Suhada D S , Rahmat F A 
Published: April 2022

Abstract

Background
Atrial fibrillation (AF) recurrence rate still stands between 40% and 50%, causing complications. Therefore, early diagnosis of AF recurrence is needed for prompt treatment, thus morbidity and mortality could be reduced and quality of life could be improved.

Aim
Determine predictive value of electrocardiogram and its findings towards AF recurrence in population who have underwent intervention.

Methods
Systematic review and meta-analysis was conducted according to PRISMA statement. Six reviewers searched studies from PubMed, ProQuest, ScienceDirect, and EBSCO from inception to June 2021 with primary outcome of AF recurrence. Data was appraised and processed using random effects or fixed effects model with the outcome of mean difference (MD) or odds ratio (OR) with 95%-confidence interval (95% CI).

Results
Thirty included studies involving 5,490 subjects were found good in terms of quality assessment. AF recurrence on patients underwent cardioversion was more likely found in patients with larger P-wave duration (OR = 2.90; 95% CI [1.47, 5.74]; p = 0.01) and P-wave dispersion (MD = 12.67 ms; 95% CI [10.73, 14.62]; p &lt; 0.00001). AF recurrence on patients underwent pulmonary vein isolation (PVI) was highly associated with larger P-wave duration (MD = 13.92 ms; 95% CI [11.54, 16.30]; p &lt; 0.00001) and P-wave dispersion (MD = 11.53 ms; 95% CI [8.41, 14.65]; p &lt; 0.00001). However, the relation between P-wave duration and AF recurrence on cathether ablation yet to be determined (MD = 6.34 ms; 95% CI [-0.77, 13.44]; p &lt; 0.00001).

Conclusion
P-wave and P-wave dispersion were considered as predictive factor for AF recurrence in patients underwent cardioversion and PVI.
M9. Five–year Outcome of Bioresorbable Vascular Scaffold versus Drug-Eluting Stent for Coronary Artery Disease: A Meta-Analysis of Randomized Control Trial
Authors: Putra H B P , Mukhammad W W , Kembangsari C , Jovie B , Juslim R R 
Published: April 2022

Abstract

Introduction
Late stent thrombosis and restenosis remain major drawbacks of Drug-Eluting Stent (DES). Therefore, Bioresorbable Vascular Scaffolds (BVS) were created to combat these disadvantages. However, the long-term outcome of BVS versus DES for treating coronary artery disease remains inconclusive.

Method
We performed an orderly literature search from several electronic databases. We used the keyword “bioresorbable vascular scaffold” and “drug-eluting stent”. The inclusion criteria were comparing BVS and DES, Randomized Control Trial (RCT), and reported 5-year follow-up. The primary endpoints were cardiac death and stent thrombosis. Secondary endpoints were ischemic-driven target lesion revascularization (ID–TLR) and target lesion failure (TLF) as a composite of cardiac death, target vessel myocardial infarction (TVMI), or ID–TLR. Risk ratio (RR) with 95% confidence intervals (CIs) were used to report all outcomes.

Results
A total of 3 RCT were selected (ABSORB II, ABSORB III, and ABSORB JAPAN) with 2.890 patients were pooled in our analysis. At five years, compared to DES, BVS had no significant difference in cardiac death (RR = 0.81 [95% CI, 0.50-1.32], p = 0.40). However, BVS had higher risk of stent thrombosis (RR = 2.74 [95% CI, 1.38-5.46], p = 0.004), ID–TLR (RR = 1.38 [95% CI, 1.04-1.84], p = 0.03) and TLF (RR = 1.26 [95% CI, 1.03-1.54], p = 0.02).

Conclusions
Comparing to DES, BVS has a significantly greater risk of stent thrombosis, ID–TLR, and TLF after five years of follow-up.
M14. The Effectiveness of Telemedicine Approach for Treating Patients with Hypertension: a meta-analysis
Authors: Haydar H , Firmanda D R 
Published: April 2022

Abstract

Background
Hypertension has become one of the major global burdens with high morbidity even in developed countries. Telemedicine intervention may be able to monitor and provide better blood pressure management in patients with hypertension.

Aims
This study evaluated the effects of telemedicine intervention on blood pressure management in patients with hypertension.

Methods
We conducted a literature search in PubMed and Cochrane Library, published up to 22 July 2021. All RCT that evaluated telemedicine intervention were included. The Cochrane risk of bias tool was used to assess the quality of the studies. The primary outcomes were systolic blood pressure (SBP), and diastolic blood pressure (DBP) changes.

Results
Sixteen RCTs were included in this analysis. Our pooled analysis showed that telemedicine was associated with reduction in SBP and DBP compared to usual care ([MD -4.21; 95% CI -5.56 to -2.85; p &lt; 0.001] and [MD -2.13; 95% CI -2.69 to -1.56; p &lt; 0,001], respectively). A subgroup analysis showed that telemedicine intervention with a period of more than six months was associated with a better reduction in SBP (MD -5.29; 95% CI -7.34 to -3.25; p &lt; 0.001).

Conclusion
Telemedicine intervention may improve the effectiveness of blood pressure in patients with hypertension.
M15. The potential benefits of renin-angiotensin-aldosterone and beta-adrenergic inhibitions for lowering trastuzumab-associated cardiotoxicity risks among breast cancer patients: meta-analysis of randomized controlled trials
Authors: Putra P , Putra F N 
Published: April 2022

Abstract

Background and Aims
Trastuzumab is one of the principal treatments for HER2-positive breast cancer patients and related to high cardiotoxicity risk. This study aims to compare the efficacies among Renin-Angiotensin-Aldosterone inhibitors (RAASi) and beta-blockers (BB) to lower trastuzumab-associated cardiotoxicity risks.

Method and Results
Comprehensive literature searching was conducted through online databases then followed the PRISMA guideline. Studies included were all randomized controlled trials (RCTs) that compared the changes of left ventricular ejection fraction (LVEF) and brain natriuretic peptides (BNP) among RAASi, BB, and placebo (PCB) in HER2-positive breast cancer patients who received trastuzumab. Bias risk was accessed by using the Cochrane Risk-of-bias (RoB 2) instrument. Analysis was performed to provide pooled risk ratio (RR) and standard mean difference (SMD) with 95% confidence interval (CI) using fixed-effect heterogeneity test. The RAASi group shows significant LVEF improvement compared with PCB (SMD=0.63, 95%CI 0.27 to 0.99, p = 0.0006, I2=0%), while the BB group also shows LVEF improvement compared with PCB although not statistically significant (SMD=0.04, 95%CI -0.32 to 0.39, p = 0.84, I2=0%). Both RAASi (SMD=0.18, 95%CI 0.00 to 0.37, p = 0.05, I2=0%) and BB (SMD=0.23, 95%CI 0.05 to 0.42, p = 0.01, I2=0%) groups have significant BNP improvement. Patients received RAASi have significant reduction of 2-year cardiac risk development (RR = 0.42, 95%CI 0.27-0.67, p = 0.0002, I2=42%) and non-significance LVEF &lt;50% reduction risk (RR = 0.49, 95%CI 0.23-1.08, p = 0.08, I2=50%).

Conclusion
Both RAASi and BB show potential benefits in lowering the trastuzumab-associated cardiotoxicity risks. However, further studies are needed to establish the efficacies.